Sugi Predict

Sugi Predict / Compounds / SCHEMBL310903

SCHEMBL310903

SCHEMBL310903

COc1cc(Br)c(F)cc1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.45
▸ PKM P14618 2/20 0.45
▸ ALDH1A1 P00352 5/20 0.44
▸ TDP1 Q9NUW8 3/20 0.44
▸ MAPK1 P28482 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ PRKDC P78527 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ POLB P06746 1/20 0.43
▸ ATM Q13315 1/20 0.42
▸ HSPB1 P04792 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ G6PD P11413 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12491675 0.93 ALDH1A1 (0.44) MAPTPKMALDH1A1TDP1MAPK1
SCHEMBL29785367 0.93 ALDH1A1 (0.44) MAPTPKMALDH1A1TDP1MAPK1
Potassium Ion SCHEMBL7698227 0.92 MAPT (0.40) MAPTPKMALDH1A1TDP1MAPK1
SCHEMBL2540530 0.86 MAPT (0.49) MAPTPKMALDH1A1TDP1MAPK1
SCHEMBL16068695 0.85 L3MBTL1 (0.60) MAPTALDH1A1TDP1MAPK1MEN1
SCHEMBL517768 0.85 ALDH1A1 (0.50) MAPTALDH1A1TDP1KDM4ECYP3A4
SCHEMBL29661436 0.85 ALDH1A1 (0.50) MAPTALDH1A1TDP1KDM4ECYP3A4
SCHEMBL5424277 0.84 ALDH1A1 (0.51) MAPTPKMALDH1A1TDP1MAPK1
SCHEMBL30954094 0.84 ALDH1A1 (0.48) MAPTALDH1A1TDP1KDM4ECYP3A4
SCHEMBL6371735 0.84 ALDH1A1 (0.48) MAPTALDH1A1TDP1KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 — — US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 — — US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 — — US disclosed
WO-2025137605-A1 COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR C4 THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
US-20250154134-A1 COMPOUND AS FAK INHIBITOR AND USE THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2025-05-15 — — US disclosed
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2025-04-10 — — US disclosed
EP-4488272-A1 COMPOUND AS FAK INHIBITOR AND USE THEREOF Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) 2025-01-08 — — EP disclosed
EP-4455139-A1 COMPOUND AS FAK INHIBITOR AND USE THEREOF Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) 2024-10-30 — — EP disclosed
CN-118574825-A Compounds as FAK inhibitors and uses thereof 微境生物医药科技(上海)有限公司 2024-08-30 — — CN disclosed
EP-1385524-A4 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2006-02-01 — — EP disclosed
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 — — US disclosed
EP-1212327-B8 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2004-02-25 — — EP disclosed
EP-1385524-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS Abbott GmbH & Co. KG (DE) 2004-02-04 — — EP disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 — — US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 — — EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed
WO-2002080926-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-17 — — WO disclosed
EP-1212327-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2002-06-12 — — EP disclosed
WO-2001019829-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2001-03-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 MAPT 1017/4885PKM 1176/4885ALDH1A1 959/4885
US-20250114460-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 MAPT 2055/4885PKM 1881/4885ALDH1A1 4008/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B MAPT 1034/4885PKM 1276/4885ALDH1A1 1225/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 MAPT 4225/4885PKM 3083/4885ALDH1A1 1790/4885
US-20250154134-A1 COMPOUND AS FAK INHIBITOR AND USE THEREOF PTK2, PAK1, FYN MAPT 1697/4885PKM 1199/4885ALDH1A1 1905/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 MAPT 1017/4885PKM 1176/4885ALDH1A1 959/4885
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 MAPT 3263/4885PKM 729/4885ALDH1A1 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.